Genprex, INC. 8-K Filing
Ticker: GNPX · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1595248
Sentiment: neutral
Filing Stats: 1,411 words · 6 min read · ~5 pages · Grade level 15.5 · Accepted 2025-11-19 07:13:17
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251116c_8k.htm (8-K) — 34KB
- 0001437749-25-035651.txt ( ) — 167KB
- gnpx-20251119.xsd (EX-101.SCH) — 3KB
- gnpx-20251119_def.xml (EX-101.DEF) — 12KB
- gnpx-20251119_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251119_pre.xml (EX-101.PRE) — 12KB
- gnpx20251116c_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 19, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing that the Company has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for the Acclaim-1 and Acclaim-3 clinical trials studying its lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in lung cancer. In addition, the Company expects to add and open additional clinical trial sites for its Acclaim clinical trials over the coming months in an effort to expand its reach to additional patients and expedite enrollment. Acclaim-1 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer ("NSCLC") who have activating EGFR mutations and disease progression after treatment with Tagrisso. The Phase 2a expansion study follows the successful completion of the Phase 1 dose escalation portion of the study, which showed REQORSA was generally well tolerated with no dose limiting toxicities despite doubling the starting dose. Importantly, the results showed early signs of efficacy with some patients experiencing prolonged progression free survival and one patient having a partial response. The Phase 2a expansion portion of the trial is expected to enroll approximately 33 patients who have previously received Tagrisso treatment and will determine the safety profile and evaluate efficacy, as well as several other exploratory endpoints. Genprex's team plans to conduct an interim analysis following the treatment of 19 patients, which the Company currently expects to complete enrollment of the first 19 patients in the first half of 2026. The Acclaim-1 clinical trial has received U.S. Food and Drug Administration ("FDA") Fast Track Designation. Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech's Tecentriq (atezolizumab) as maintenance therapy in patients with extensive sta
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 19, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)